中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
8期
534-537
,共4页
高佳%刘彦慧%阎玲%陈小岑(综述)%赵路军(审校)
高佳%劉彥慧%閻玲%陳小岑(綜述)%趙路軍(審校)
고가%류언혜%염령%진소잠(종술)%조로군(심교)
脑转移瘤%瘤周水肿%分子生物学%研究进展
腦轉移瘤%瘤週水腫%分子生物學%研究進展
뇌전이류%류주수종%분자생물학%연구진전
metastasis tumor of brain%peritumoral edema%molecular biology%research progress
脑转移瘤瘤周水肿指脑转移肿瘤周围脑实质内水分的异常增多,是影响患者生活质量和治疗疗效的关键因素之一,其发生机制复杂,影响因素众多。可能与血管内皮生长因子及其受体、水通道蛋白-4、金属基质蛋白酶-9、白细胞介素-6、乏氧诱导因子及其他分子生物学因素有关,上述分子生物学因素的深入研究可以为瘤周水肿的防治、监测、治疗及预后提供依据。瘤周水肿的治疗除传统的脱水治疗外,相关分子生物学因素的运用可以为其提供新的途径和方向,其中水通道蛋白-4激动剂或拮抗剂,血管内皮生长因子受体拮抗剂已逐步在临床中得到初步应用。本文就脑转移瘤瘤周水肿相关分子生物学因素进行综述。
腦轉移瘤瘤週水腫指腦轉移腫瘤週圍腦實質內水分的異常增多,是影響患者生活質量和治療療效的關鍵因素之一,其髮生機製複雜,影響因素衆多。可能與血管內皮生長因子及其受體、水通道蛋白-4、金屬基質蛋白酶-9、白細胞介素-6、乏氧誘導因子及其他分子生物學因素有關,上述分子生物學因素的深入研究可以為瘤週水腫的防治、鑑測、治療及預後提供依據。瘤週水腫的治療除傳統的脫水治療外,相關分子生物學因素的運用可以為其提供新的途徑和方嚮,其中水通道蛋白-4激動劑或拮抗劑,血管內皮生長因子受體拮抗劑已逐步在臨床中得到初步應用。本文就腦轉移瘤瘤週水腫相關分子生物學因素進行綜述。
뇌전이류류주수종지뇌전이종류주위뇌실질내수분적이상증다,시영향환자생활질량화치료료효적관건인소지일,기발생궤제복잡,영향인소음다。가능여혈관내피생장인자급기수체、수통도단백-4、금속기질단백매-9、백세포개소-6、핍양유도인자급기타분자생물학인소유관,상술분자생물학인소적심입연구가이위류주수종적방치、감측、치료급예후제공의거。류주수종적치료제전통적탈수치료외,상관분자생물학인소적운용가이위기제공신적도경화방향,기중수통도단백-4격동제혹길항제,혈관내피생장인자수체길항제이축보재림상중득도초보응용。본문취뇌전이류류주수종상관분자생물학인소진행종술。
Peritumoral edema (PTE) of the metastasis tumor of brain (MTB) refers to the abnormal increase of moisture in the surrounding cerebral parenchyma of the brain tumor. The mechanism of PTE occurrence of MTB is complicated, and the influencing factors are diverse. PTE is one of the key factors that affect patient survival and cure. Researchers from China and overseas believe that it may be related to the expression of the vascular endothelial growth factor (VEGF) or VEGF receptor, aquaporin-4 (AQP-4), matrix metalloproteinase-9, interleukin-6, hypoxia inducible factor-1a, and other molecular biology factors. Studies of these molecular biologi-cal factors provide objective scientific evidence for the prevention, control, monitoring, treatment, and prognosis of PTE of metasta-sized brain tumor. In addition to the traditional dehydration therapy of PTE, the use of PTE-related molecular biological factors pro-vides a new approach for the treatment. AQP-4 agonists or antagonists and VEGF receptor antagonists also have good therapeutic poten-tials. In this paper, the authors reviewed the PTE-related molecular biological factors of MTB.